Biosig Technologies Inc logo

BSGM - Biosig Technologies Inc News Story

$3.49 0.1  1.7%

Last Trade - 21/04/21

Small Cap
Market Cap £79.7m
Enterprise Value £60.0m
Revenue £n/a
Position in Universe 5053rd / 6852

BioSig CEO Kenneth L. Londoner to Present at the Virtual Investor Conference Small and Microcap Showcase

Wed 27th January, 2021 9:30pm
For best results when printing this announcement, please click on link below:

Westport, CT, Jan. 27, 2021 (GLOBE NEWSWIRE) --
* Company to provide corporate overview and progress on the rollout of the
PURE EP™ System
BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a
medical technology company commercializing an innovative signal processing
platform designed to improve signal fidelity and uncover the full range of ECG
and intra-cardiac signals, today announced that it will present at the Virtual
Investor Conference Small and Microcap Showcase on February 4, 2021.

During the presentation, Kenneth L. Londoner, Chairman, and CEO of BioSig
Technologies, Inc. will provide a Company overview that includes recent
updates on the rollout of BioSig’s PURE EP™ System and other business
highlights. To date, more than 470 patient procedures have been conducted with
the PURE EP ™ System by more than 32 electrophysiologists across seven
different clinical sites in the United States.

Event: Virtual Investor Conference Small and Microcap Showcase
Presentation Date: Thursday, February 4, 2021
Presentation Time: 11:30 AM Eastern

To register, Click here

About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor
conference series that provides an interactive forum for publicly traded
companies to meet and present directly with investors.

A real-time solution for investor engagement, Virtual Investor Conferences is
part of OTC Market Group's suite of investor relations services specifically
designed for more efficient Investor Access. Replicating the look and feel of
on-site investor conferences, Virtual Investor Conferences combine
leading-edge conferencing and investor communications capabilities with a
comprehensive global investor audience network.

About BioSig Technologies 
BioSig Technologies is a medical technology company commercializing a
proprietary biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac signals

The Company’s first product, PURE EP (tm) System is a computerized system
intended for acquiring, digitizing, amplifying, filtering, measuring and
calculating, displaying, recording and storing of electrocardiographic and
intracardiac signals for patients undergoing electrophysiology (EP) procedures
in an EP laboratory.

Forward-looking Statements 
This press release contains “forward-looking statements.” Such statements
may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or
similar words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to various known
and unknown risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently, actual
results may differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include, without
limitation, risks and uncertainties associated with (i) the geographic, social
and economic impact of COVID-19 on our ability to conduct our business and
raise capital in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own, or in
collaboration with third parties; (iii) difficulties in obtaining financing on
commercially reasonable terms; (iv) changes in the size and nature of our
competition; (v) loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products and
product candidates. More detailed information about the Company and the risk
factors that may affect the realization of forward-looking statements is set
forth in the Company’s filings with the Securities and Exchange Commission
(SEC), including the Company’s Annual Report on Form 10-K and its Quarterly
Reports on Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at The
Company assumes no obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or otherwise.

Andrew Ballou
BioSig Technologies, Inc. 
Vice President, Investor Relations 
54 Wilton Road, 2nd floor
Westport, CT 06880
203-409-5444, x133


GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.